BERLIN-- (BUSINESS WIRE)-- Crescendo Bioscience ®, Inc., a molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis (RA) and other inflammatory diseases, today ...
Crescendo wants to boost commercialization of its RA blood test--courtesy of Crescendo Bioscience. With a $28 million Series D venture round now in place, Crescendo Bioscience is focusing on boosting ...
Myriad Genetics ($MYGN) paid $270 million for Crescendo Bioscience in February and isn't wasting any time promoting the accomplishments of its now wholly owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results